Retina

Imagine prescribing eye drops to treat wet AMD, or delivering genes to the retina of patients with retinitis pigmentosa. Nanotechnology can do both – and it could potentially transform ophthalmology

Popular culture has always viewed eyes as being things of beauty. But there’s more to the eye than the color of your irides.

Oral replacement therapy of the retinoid intermediate that fails to form in some types of Leber congenital amaurosis shows significant promise in an early-phase clinical trial

Might you soon take a skin cell from a patient with retinitis pigmentosa, roll it back to a pluripotent state, culture it to become retinal cells and trial gene therapy on it in vitro?

Population-level disease prophylaxis with statins has improved the lives of millions. But there has been some protest about this mass medication. Is the next battle not with disease, but with the press?

One of the most debilitating microvascular complications of diabetes is diabetic retinopathy, the most important cause of blindness among working age adults in developed countries.

As the prevalence of diabetes increases worldwide, so too do the complications relating to it, such as diabetic macular edema (DME).

Diabetic macular edema (DME) poses a significant management dilemma for visual impairment.

Diabetic macular edema (DME) may occur when blood vessels leak contents into the macular region.

Diabetic maculopathy is the most common cause of visual impairment in individuals with diabetes.